Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27815086.
- Also identified by DOI 10.1016/j.eururo.2016.10.029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies are key stepping stones towards successful delivery of surgical RCTs.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Cytoreduction Surgical Procedures
- Kidney Neoplasms
- Nephrectomy
- Protein Kinase Inhibitors